Evidence Synthesis
Wockhardt Pharmaceuticals Sees Significant Improvement in Gross Margin and Marginal Operating Leverage.
The company's gross margin accelerated to , up from 14.82%. This indicates a substantial increase in the company's profitability.
Additionally, its marginal operating leverage accelerated to , up from 6.32%. This suggests that the company's ability to generate earnings from its operations has improved.
These improvements come against a backdrop of declining daily volume, with the company's trading 610,781 shares on July 8, 2026, down from 2,44,03,404 shares on the previous day.
The close price also moved lower, down 0.013 INR from 1,857.4 INR on July 7, 2026.
By paying you agree to our Terms and Privacy Policy.